First-Line RCC Treatment Cleared in Sunitinib Labeling
New labeling of Sutent (sunitinib malate, Pfizer) has been approved that includes first-line treatment of advanced renal cell carcinoma (RCC).
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.